GENB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Generate Biomedicines, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 14.00 USD
4.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is - below the Trend Line and sits at 41.8% of its 52-week range. The latest completed week returned 4.5%, after a -19.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 27 out of 100
Latest Close 14.00 USD 31 Jul 2026
1W Return 4.5% latest completed week
4W Return -19.6% short-term follow-through
12W Return 2.5% quarterly tape
Trend Breadth 0.0% 0 of 23 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • 4 reversal markers appear in the recent smart-money tape.
What to watch next
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.5% Latest completed week; four-week move -19.6%. Indicator stack 0/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 51/100 42 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is - below the Trend Line and sits at 41.8% of its 52-week range. The latest completed week returned 4.5%, after a -19.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2812-week average 0.18

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.28Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -19.6% over four weeks, 2.5% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.5%
4W-19.6%
12W2.5%
26W-
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 70% Model confidence 67%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength60/100Blend of value, momentum, and quality. Underlying universe rank 41; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality52/100Profitability and accounting quality. Underlying universe rank 49; rank 1 is best.
Momentum54/100Medium-term price momentum. Underlying universe rank 47; rank 1 is best.
Growth54/100Revenue and earnings growth. Underlying universe rank 47; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
53.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-12.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
100.0%
Gross profit retained from each unit of revenue.
Operating margin
-695.0%
Operating profit retained from revenue.
Free-cash-flow margin
-618.0%
Free cash flow generated from revenue.
Return on invested capital
-39.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
55.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-1.3%
Net share repurchases relative to market value.
Shareholder yield
-1.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 42 relevant articles.

8 positive · 31 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-23.0%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2211 weeks finished lower.
Best week+20.2%Week of 3 Apr.
Worst week-17.7%Week of 10 Jul.
Latest week+4.5%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains3
Flat weeks0
Modest losses3
Sharp losses8
Recent vol10.2%13-week weekly-return volatility.
Base vol11.0%52-week weekly-return volatility.
Up/down split11/11Count of positive and negative weeks in the 52-week window.
Average skew10.3% / -8.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis6/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.28; 4 reversal markers Factors54/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 77; Small Cap Core rank 52 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 42 relevant articles.

Top Generate Biomedicines (GENB) Competitors 2026 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202614.00 USD4.5%-13.50 USD0.00-3.2MOff
24 Jul 202613.40 USD-1.2%-13.47 USD0.00-1.9MOff
17 Jul 202613.56 USD-5.3%-13.48 USD0.00-2.3MOff
10 Jul 202614.32 USD-17.7%-13.47 USD0.00-4.2MOff
3 Jul 202617.41 USD5.7%-13.43 USD0.00-4.8MOff
26 Jun 202616.47 USD13.7%-13.21 USD0.00-7.7MOff
19 Jun 202614.49 USD17.0%-13.02 USD0.00-4.7MOff
12 Jun 202612.38 USD-3.8%-12.92 USD0.00-3.0MOff
5 Jun 202612.87 USD-1.9%-12.96 USD0.00-6.8MOff
29 May 202613.12 USD-9.7%-12.97 USD0.00-2.5MOff
22 May 202614.53 USD-9.2%-12.95 USD0.00-5.1MOff
15 May 202616.00 USD17.1%-12.82 USD0.00-2.9MOff
8 May 202613.66 USD3.9%-12.53 USD0.00-1.4MOff
1 May 202613.15 USD2.7%-12.42 USD0.00-1.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.